Cell Source Stock Price To Earning
| CLCS Stock | USD 0.54 0.04 8.00% |
Cell Source fundamentals help investors to digest information that contributes to Cell Source's financial success or failures. It also enables traders to predict the movement of Cell OTC Stock. The fundamental analysis module provides a way to measure Cell Source's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cell Source otc stock.
Cell |
Cell Source OTC Stock Price To Earning Analysis
Cell Source's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Cell Source Price To Earning | (3.28) X |
Most of Cell Source's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cell Source is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Cell Source has a Price To Earning of -3.28 times. This is 112.69% lower than that of the Healthcare sector and 166.53% lower than that of the Biotechnology industry. The price to earning for all United States stocks is 111.42% higher than that of the company.
Cell Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cell Source's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cell Source could also be used in its relative valuation, which is a method of valuing Cell Source by comparing valuation metrics of similar companies.Cell Source is currently under evaluation in price to earning category among its peers.
Cell Fundamentals
| Return On Asset | -3.78 | |||
| Current Valuation | 59.65 M | |||
| Shares Outstanding | 35.25 M | |||
| Shares Owned By Insiders | 32.13 % | |||
| Price To Earning | (3.28) X | |||
| EBITDA | (4.11 M) | |||
| Net Income | (5.47 M) | |||
| Cash And Equivalents | 93.09 K | |||
| Total Debt | 6.5 M | |||
| Debt To Equity | (1.04) % | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | (0.34) X | |||
| Cash Flow From Operations | (3.38 M) | |||
| Earnings Per Share | (0.20) X | |||
| Beta | -64.41 | |||
| Market Capitalization | 10.61 M | |||
| Total Asset | 313.77 K | |||
| Retained Earnings | (21.7 M) | |||
| Working Capital | (7.79 M) | |||
| Current Asset | 213.56 K | |||
| Current Liabilities | 8 M | |||
| Net Asset | 313.77 K |
About Cell Source Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cell Source's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cell Source using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cell Source based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cell OTC Stock Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.